Literature DB >> 34760975

Targeting resolvins in cholestatic liver injury.

Luis A Videla1, Rodrigo Valenzuela2.   

Abstract

Entities:  

Year:  2021        PMID： 34760975      PMCID： PMC8527424          DOI： 10.21037/hbsn-2021-15

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  13 in total

Review 1.  Resolvin D1 and its GPCRs in resolution circuits of inflammation.

Authors:  Antonio Recchiuti
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-15       Impact factor: 3.072

2.  Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-κB and MAPK pathways and activating the Nrf2 pathway in mice.

Authors:  Jiahuan Li; Xiaoling Deng; Tao Bai; Shuhan Wang; Qianqian Jiang; Keshu Xu
Journal:  Int Immunopharmacol       Date:  2020-10-13       Impact factor: 4.932

Review 3.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

4.  Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation.

Authors:  Yee-Ping Sun; Sungwhan F Oh; Jasim Uddin; Rong Yang; Katherine Gotlinger; Eric Campbell; Sean P Colgan; Nicos A Petasis; Charles N Serhan
Journal:  J Biol Chem       Date:  2007-01-23       Impact factor: 5.157

5.  Resolvin D series and protectin D1 mitigate acute kidney injury.

Authors:  Jeremy S Duffield; Song Hong; Vishal S Vaidya; Yan Lu; Gabrielle Fredman; Charles N Serhan; Joseph V Bonventre
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

6.  Suppression of high-fat diet-induced obesity-associated liver mitochondrial dysfunction by docosahexaenoic acid and hydroxytyrosol co-administration.

Authors:  Macarena Ortiz; Sandra A Soto-Alarcón; Paula Orellana; Alejandra Espinosa; Cristian Campos; Sandra López-Arana; Miguel A Rincón; Paola Illesca; Rodrigo Valenzuela; Luis A Videla
Journal:  Dig Liver Dis       Date:  2020-06-30       Impact factor: 4.088

7.  Docosahexaenoic acid and hydroxytyrosol co-administration fully prevents liver steatosis and related parameters in mice subjected to high-fat diet: A molecular approach.

Authors:  Sandra A Soto-Alarcón; Macarena Ortiz; Paula Orellana; Francisca Echeverría; Andrés Bustamante; Alejandra Espinosa; Paola Illesca; Daniel Gonzalez-Mañán; Rodrigo Valenzuela; Luis A Videla
Journal:  Biofactors       Date:  2019-08-27       Impact factor: 6.113

Review 8.  Combined docosahexaenoic acid and thyroid hormone supplementation as a protocol supporting energy supply to precondition and afford protection against metabolic stress situations.

Authors:  Luis A Videla
Journal:  IUBMB Life       Date:  2019-05-15       Impact factor: 3.885

9.  Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.

Authors:  Kerstin Abshagen; Alexander Hartmann; Laura Grüner; Marie Liebig; Brigitte Vollmar
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

10.  The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease.

Authors:  Roddy Hiram; Feng Xiong; Patrice Naud; Jiening Xiao; Martin Sirois; Jean-François Tanguay; Jean-Claude Tardif; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.